Intravenous immunoglobulin therapy in neonatal immune hemolytic jaundice
Authors:
- Ilan AradIAIlan Arad
- 1 January 1993
- journal article
- Published by Walter de Gruyter GmbH in Journal of Perinatal Medicine
- Vol. 21 (3) , 183-187
Abstract
Nine cases of newborn patients who developed hyperbilirubinemia due to blood group incompatibility and were treated with high dose (1 gram/Kg) intravenous immunoglobulin (IVIG) are described. In 7 of the 9 patients the rise of bilirubin level was attenuated and exchange transfusion was not required following treatment with IVIG. Of the two patients who did require an exchange transfusion despite IVIG treatment, one had the exchange performed immediately following the IVIG infusion, allowing no time for observation of the therapy effect. Our results suggest that IVIG administration may be efficacious in the treatment of immune hemolytic hyperbilirubinemia of the newborn but further studies are required to validate the efficacy of this treatment.Keywords
This publication has 5 references indexed in Scilit:
- Use of intravenously administered immune globulin in newborn infants: Prophylaxis, treatment, both, or neither?The Journal of Pediatrics, 1991
- High‐Dose Intravenous Gammaglobulin Therapy for Neonatal Immune Haemolytic Jaundice due to Blood Group IncompatibilityActa Paediatrica, 1991
- Intravenous gammaglobulin therapy for prophylaxis of infection in high-risk neonatesThe Journal of Pediatrics, 1987
- High-dose intravenous gammaglobulin therapy for passive immune thrombocytopenia in the neonateThe Journal of Pediatrics, 1983
- Substitutive-Inhibitory Gamma Globulin Therapy as Prevention of Stillbirth in Rh–IncompatibilityActa Haematologica, 1965